verapamil has been researched along with Carcinoma, Renal Cell in 9 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Toxicities included hypotension, asymptomatic bradycardia, and mild atrioventricular conduction delays, although one patient had dexverapamil discontinued for grade IV congestive heart failure." | 5.08 | Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. ( Cordon-Cardo, C; Fischer, P; Lianes, P; Lyn, P; Motzer, RJ; Ngo, RL; O'Brien, JP, 1995) |
| "Cells from 22 renal cell carcinomas (RCC) were established in culture." | 1.29 | Verapamil enhances doxorubicin activity in cultured human renal carcinoma cells. ( Collins, CM; Hall, P; Lai, T; Morgan, AP; Smith, PJ; Stonebridge, BR; Symes, MO, 1993) |
| "Human renal adenocarcinomas do not adequately respond to cancer chemotherapy." | 1.29 | [Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma]. ( Deguchi, T; Ehara, H; Kawada, Y; Kawamoto, S; Nezasa, S; Okano, M; Tamaki, M; Yamada, S, 1996) |
| "Multidrug resistance in human renal cell carcinoma is mainly caused by expression of the MDR1 gene and is characterized by a broad spectrum cross resistance to many natural product chemotherapeutic agents." | 1.28 | New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene. ( Aiken, PM; Gottesman, MM; Merlino, GT; Mickisch, GH; Pastan, I, 1991) |
| "Human renal cell carcinomas show a high degree of intrinsic multidrug resistance." | 1.28 | Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. ( Alken, PM; Forster, S; Koessig, J; Mickisch, GH; Roehrich, K; Tschada, RK, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 6 (66.67) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Strobbe, G | 1 |
| Pannier, D | 1 |
| Sakji, I | 1 |
| Villain, A | 1 |
| Feutry, F | 1 |
| Marliot, G | 1 |
| Motzer, RJ | 1 |
| Lyn, P | 1 |
| Fischer, P | 1 |
| Lianes, P | 1 |
| Ngo, RL | 1 |
| Cordon-Cardo, C | 1 |
| O'Brien, JP | 1 |
| Lai, T | 1 |
| Collins, CM | 1 |
| Hall, P | 1 |
| Morgan, AP | 1 |
| Smith, PJ | 1 |
| Stonebridge, BR | 1 |
| Symes, MO | 1 |
| Mickisch, GH | 3 |
| Noordzij, MA | 1 |
| vd Gaast, A | 1 |
| Gebreamlack, P | 1 |
| Köhrmann, KU | 1 |
| Mogler-Drautz, E | 1 |
| Kupper, H | 1 |
| Schröder, FH | 1 |
| Okano, M | 1 |
| Kawamoto, S | 1 |
| Nezasa, S | 1 |
| Tamaki, M | 1 |
| Ehara, H | 1 |
| Yamada, S | 1 |
| Deguchi, T | 1 |
| Kawada, Y | 1 |
| Yu, DS | 1 |
| Sun, GH | 1 |
| Ma, CP | 1 |
| Chang, SY | 1 |
| Merlino, GT | 1 |
| Aiken, PM | 1 |
| Gottesman, MM | 1 |
| Pastan, I | 1 |
| Roehrich, K | 1 |
| Koessig, J | 1 |
| Forster, S | 1 |
| Tschada, RK | 1 |
| Alken, PM | 1 |
| Watanabe, Y | 1 |
2 trials available for verapamil and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bradycardia; Carcinoma, Renal | 1995 |
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
7 other studies available for verapamil and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: A case report.
Topics: Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Everolimus; Female; Humans; Immunosuppres | 2020 |
Verapamil enhances doxorubicin activity in cultured human renal carcinoma cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Carrier Proteins; Do | 1993 |
[Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Bloc | 1996 |
Verapamil modulation of multidrug resistance in renal cell carcinoma.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Doxorubicin; Drug Re | 2000 |
New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Daunorubici | 1991 |
Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.
Topics: Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; But | 1990 |
[Enhancement of cytotoxicity of anticancer drugs by verapamil--effects on established human renal tumor cell line].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitum | 1988 |